AQST vs. AUPH, COLL, SNDX, SYRE, ELVN, BCYC, NTLA, ZYME, RCKT, and GYRE
Should you be buying Aquestive Therapeutics stock or one of its competitors? The main competitors of Aquestive Therapeutics include Aurinia Pharmaceuticals (AUPH), Collegium Pharmaceutical (COLL), Syndax Pharmaceuticals (SNDX), Spyre Therapeutics (SYRE), Enliven Therapeutics (ELVN), Bicycle Therapeutics (BCYC), Intellia Therapeutics (NTLA), Zymeworks (ZYME), Rocket Pharmaceuticals (RCKT), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry.
Aquestive Therapeutics vs.
Aquestive Therapeutics (NASDAQ:AQST) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership, community ranking and dividends.
In the previous week, Aquestive Therapeutics had 5 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 6 mentions for Aquestive Therapeutics and 1 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 1.01 beat Aquestive Therapeutics' score of 0.78 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.
Aquestive Therapeutics has higher earnings, but lower revenue than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Aquestive Therapeutics, indicating that it is currently the more affordable of the two stocks.
Aquestive Therapeutics has a beta of 2.71, meaning that its stock price is 171% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500.
32.5% of Aquestive Therapeutics shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 7.9% of Aquestive Therapeutics shares are owned by insiders. Comparatively, 4.3% of Aurinia Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Aurinia Pharmaceuticals received 361 more outperform votes than Aquestive Therapeutics when rated by MarketBeat users. Likewise, 73.27% of users gave Aurinia Pharmaceuticals an outperform vote while only 68.17% of users gave Aquestive Therapeutics an outperform vote.
Aurinia Pharmaceuticals has a net margin of -10.23% compared to Aquestive Therapeutics' net margin of -59.75%. Aquestive Therapeutics' return on equity of 0.00% beat Aurinia Pharmaceuticals' return on equity.
Aquestive Therapeutics currently has a consensus target price of $11.00, indicating a potential upside of 254.84%. Aurinia Pharmaceuticals has a consensus target price of $10.00, indicating a potential upside of 24.84%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Aquestive Therapeutics is more favorable than Aurinia Pharmaceuticals.
Summary
Aquestive Therapeutics beats Aurinia Pharmaceuticals on 11 of the 19 factors compared between the two stocks.
Get Aquestive Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aquestive Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:AQST) was last updated on 1/20/2025 by MarketBeat.com Staff
